Physician profile
Jay S Edmonds
NPI 1619944881
$2,522.95
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $255 · 2021: $61.42 · 2022: $399 · 2023: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.78 | 2019-2023 | Qulipta |
| Glaxosmithkline, LLC. | $321.65 | 2019-2023 | Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $187.68 | 2019-2020 | |
| Mylan Specialty L.P. | $173.86 | 2019-2023 | Yupelri |
| Pfizer INC. | $133.54 | 2019-2023 | |
| Lilly USA, LLC | $125.09 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $123.47 | 2019-2023 | Rybelsus, Ozempic |
| Amag Pharmaceuticals, INC. | $114.54 | 2019 | |
| Abbott Laboratories | $113.37 | 2022-2023 | Freestyle Libre 3 |
| Amgen INC. | $108.59 | 2019-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.07 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $71.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $64.93 | 2019 | |
| Allergan, INC. | $61.46 | 2019-2020 | |
| Seqirus USA INC | $55.53 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $55.50 | 2019 | |
| Therapeuticsmd, INC. | $45.74 | 2019-2022 | |
| Daiichi Sankyo INC. | $42.67 | 2019 | |
| Biodelivery Sciences International, INC. | $39.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.15 | 2019 | |
| Dexcom, INC. | $28.02 | 2023 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $22.81 | 2019 | |
| Esperion Therapeutics, INC. | $22.72 | 2021 | |
| Horizon Therapeutics Plc | $22.65 | 2019 | |
| Sanofi Pasteur INC. | $22.11 | 2019 | |
| Smith+Nephew, INC. | $21.63 | 2022 | |
| Amarin Pharma, INC. | $21.61 | 2020 | |
| Exact Sciences Corporation | $20.99 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.03 | 2019 | |
| Gilead Sciences, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Edmonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.